Popular terms

[SEARCH]

Histidine topics
Amino Acid
Amino Acids
Genetically
Antibodies
Immunoglobulin
Polypeptide
Nucleic Acid
Pertuzumab
Trastuzumab
Mesoporous Silica
Hemoglobin
Specificity
Carrier Molecule
Blood Plasma
Recombinant

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Histidine patents



      
           
This page is updated frequently with new Histidine-related patent applications. Subscribe to the Histidine RSS feed to automatically get the update: related Histidine RSS feeds. RSS updates for this page: Histidine RSS RSS



Date/App# patent app List of recent Histidine-related patents
07/30/15
20150211093 
 Gallium extraction agent and gallium extraction method patent thumbnailnew patent Gallium extraction agent and gallium extraction method
Provided are an extraction agent and extraction method that selectively extract and, at a low cost, recover gallium from an acidic solution containing gallium and zinc. The gallium extraction agent comprises an amide derivative represented by general formula (1).
Sumitomo Metal Mining Co., Ltd.


07/23/15
20150203881 
 Method for producing an l-amino acid using a bacterium of the enterobacteriaceae family patent thumbnailMethod for producing an l-amino acid using a bacterium of the enterobacteriaceae family
A method for producing an l-amino acid is described, for example l-threonine, l-lysine, l-histidine, l-phenylalanine, l-arginine, l-tryptophan, or l-glutamic acid, using a bacterium of the enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of a wild-type alcohol dehydrogenase encoded by the adhe gene or a mutant alcohol dehydrogenase which is resistant to aerobic inactivation.. .
Ajinomoto Co., Inc.


07/23/15
20150201663 
 Protein hydrolysate patent thumbnailProtein hydrolysate
The present invention relates to a protein hydrolysate, wherein the hydrolysate has a percentage of peptides having a histidine residue at the c-terminal end of at least 10 wt % of the total peptide content of the protein hydrolysate and a process for preparing the protein hydrolysate. The invention further relates to a food or feed product comprising the protein hydrolysate..
Dsm Ip Assets B.v.


07/16/15
20150196642 
 Antibody formulations patent thumbnailAntibody formulations
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain ii of her2 (for example, pertuzumab), and a formulation comprising an antibody that binds to dr5 (for example, apomab).. .
Genentech, Inc.


07/09/15
20150190478 
 New protecting compositions for recombinantly produced factor vii patent thumbnailNew protecting compositions for recombinantly produced factor vii
A histidine-free composition comprising: a high purity factor viii (r-factor viii); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor viii; an amount of calcium chloride for specific stabilization of factor viii.. .
Octapharma Ag


06/25/15
20150174208 
 Cosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly patent thumbnailCosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly
The invention is a cosmetic and pharmaceutical liposomal composition which comprises a mixture of carboxylated oligopeptides derived from natural polypeptides; insulin; hyaluronidase and collagenase by their enzymatic hydrolysis; followed by a carboxylation of the free amino groups of lysine, histidine, and additional hydrolysis of terminal amino groups in the oligopeptides. Natural polypeptides may be hydrolyzed with a proteolytic enzyme to form a mixture of oligopeptides and succinylated them.

06/18/15
20150166620 
 Vaccine patent thumbnailVaccine
The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (x3)mkdx2qlgx1 (seq id no. 99), wherein x1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, x2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine.
Affiris Ag


06/11/15
20150160230 
 Methods of predicting and decreasing the risk of pre-term birth patent thumbnailMethods of predicting and decreasing the risk of pre-term birth
Provided are methods for predicting the risk of pre-term birth in a pregnant subject, for identifying a subject having an increased risk of pre-term birth, for selecting a subject for participation in a clinical study, and for decreasing the risk of pre-term birth in a subject. These methods include providing a sample from the subject and detecting the level of one or more of growth arrest-specific protein 1 (gasi), alli-fused gene from chromosome 4 protein (ar4)/fragile x mental retardation 2 (fmr2) family member 3 (aff3), transthyretin (ttr), ryanodine receptor 1 (ryri), e26 transformation specific variant 6 (etv6), claudin-10, zinc finger protein 23 (znf23), collagen type xxvii α1 (col27ai), kazrin isoform-1, keratin-associated protein 10-9 (krtapio-9), huntingtin (htt), microtubule associated protein 9 (map9), coiled-coil domain-containing protein 13 (ccdc13), inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase isoform 2 (hisppdi), immunoglobulin gamma-3 chain c (ig-hg3), cysteine- and histidine-rich protein-1 (cyhri), and xp 002348181..
University Of Louisville Research Foundation, Inc.


06/11/15
20150159146 
 Mutant neq hs dna polymerase derived from nanoarchaeum equitans and its application to hot-start pcr patent thumbnailMutant neq hs dna polymerase derived from nanoarchaeum equitans and its application to hot-start pcr
A dna polymerase (neq dna polymerase) derived from nanoarchaeum equitans is split into neq l and neq s fragments, each of which contains inteins. A neq hot-start (hs) dna polymerase in which the inteins of the neq l and neq s fragments are linked with each other is provided in the form of a precursor of neq dna polymerase.
Research & Business Foundation Sungkyunkwan University


06/04/15
20150151974 
 Method for preparing zinc-histidine self-assembly biomimetric complex, zinc-histidine self-assembly complex prepared by said method, and  reducing carbon dioxide using said zinc-histidine self-assembly complex patent thumbnailMethod for preparing zinc-histidine self-assembly biomimetric complex, zinc-histidine self-assembly complex prepared by said method, and reducing carbon dioxide using said zinc-histidine self-assembly complex
Method for preparing zinc-histidine self-assembly biomimetic complex activating reaction to convert carbon dioxide into bicarbonate ion, zinc-histidine self-assembly biomimetic complex by preparation method, and method for reducing carbon dioxide using zinc-histidine self-assembly biomimetic complex. The preparation includes: mixing l-histidine and p-toluene sulfonic acid in first organic solvent to form first mixed solution and recrystallizing first mixed solution with ethyl ether to prepare first mixed substance: mixing first mixed substance with azelaic acid in second organic solvent to form second mixed substance containing imidazole and amide groups; mixing second mixed substance with naoh and hcl in third organic solvent to form third mixed solution and recrystallizing third mixed solution with ethyl ether to prepare third mixed substance having amphiphilic characteristic: and mixing third mixed substance with aqueous solution of zinc precursor and causing self-assembly to prepare zinc-containing self-assembly biomimetic complex..
Industry-academic Cooperation Foundation Yonsei University


06/04/15
20150150982 

Pharmaceutical formulation for a therapeutic antibody


The present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an igg, said formulation comprising at least acetate/acidic acid, arginine, and trehalose. In addition, the present invention relates to pharmaceutical formulations for a therapeutical antibody, preferably an igg, said formulation comprising at least histidine, mannitol and/or succinate and trehalose..
Boehringer Ingelheim International Gmbh


06/04/15
20150150964 

Herpesvirus compositions and related methods


The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization..
Sanofi Pasteur Biologics, Llc


05/21/15
20150141322 

Therapeutic agent, treatment method and inspection diseases caused by activation or neutrophils


The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (hrg) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation.
National University Corporation Okayama University


05/21/15
20150140139 

Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same


The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. Ala, which is the photosensitizer of the present invention, is preferably activated by led radiation, and more preferably activated by radiation having a long wavelength of 650 to 675 nm.
Gwangju Institute Of Science And Technology


05/14/15
20150132279 

Radiation sterilization-resistant protein composition


A protein composition which comprises a mixture of glycine, phenylalanine and histidine and/or a cellulose ether derivative as an additive and has resistance to radiation sterilization.. .

05/07/15
20150122271 

Thermal treatment process for tobacco materials


A method of preparing a tobacco material for use in a smoking article is provided, including (i) mixing a tobacco material, water, and an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, di- and trivalent cations, asparaginase, saccharides, phenolic compounds, reducing agents, compounds having a free thiol group, oxidizing agents, oxidation catalysts, plant extracts, and combinations thereof; (ii) heating the mixture; and (iii) incorporating the heat-treated mixture into a smoking article as a smokable material. A smoking article in the form of a cigarette is also provided that includes a tobacco material pre-treated to inhibit reaction of asparagine to form acrylamide in mainstream smoke.
R. J. Reynolds Tobacco Company


04/30/15
20150119556 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.


04/30/15
20150118322 

Biomedical composition


The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or c4-c20 alkane, wherein the modified histidine and the polymer or c4-c20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or c4-c20 alkane is about 0-40%.. .
Industrial Technology Research Institute


04/23/15
20150112047 

Adapter molecule capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag and methods of using the same


Disclosed is a bifunctional adapter molecule comprising two binding moieties a and b, the adapter molecule being capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag, wherein the binding moiety a comprises at least two chelating groups k, wherein each chelating group is capable of binding to a transition metal ion, thereby rendering moiety a capable of binding to an oligohistidine affinity tag, and the binding moiety b is an affinity tag other than an oligohistidine tag.. .
Iba Gmbh


03/26/15
20150086537 

Highly concentrated pharmaceutical formulations


The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-cd20 antibody, such as e.g. Rituximab, ocrelizumab, or humab<cd20>, or a mixture of such antibody molecules for subcutaneous injection.
Genentech, Inc.


03/19/15
20150080554 

Affinity chromatography matrix


The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal protein a (e, d, a, b, c) or protein z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to h18 of the b domain of protein a or of protein z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to h18 of the b domain of protein a or of protein z is not serine, threonine or lysine.. .
Ge Healthcare Bio-sciences Ab


03/19/15
20150080291 

Short antimicrobial lipopeptides


Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of kpv or kdpt that exhibit antimicrobial activity.
Helix Biomedix Inc.


03/12/15
20150071959 

Neisseria meningitidis compositions and methods thereof


In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride.
Pfizer Inc.


03/12/15
20150071944 

Stable antibody compositions and methods of stabilizing same


The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human igg molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of il-12/il-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation..
Abbvie, Inc.


03/05/15
20150065395 

Compositions and methods for analyzing histidine phosphorylation


A peptide is disclosed of the general structure: z—w—y, wherein z and y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and w is a non-hydrolyzable phis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies.
Sanofi


02/26/15
20150056696 

Recombinant lentiviral vector preparation


Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a ph value of the preparation in the range of 6.0-8.0; and c) a carbohydrate.. .
Beijing Solobio Genetechnology Company Ltd.


02/12/15
20150045219 

Abiotic and biotic stress tolerance peptides and polynucleotides, and compositions and methods comprising them


X is an amino acid chosen from alanine (a), cysteine (c), aspartic acid (d), glutamic acid (e), phenylalanine (f), glycine (g), histidine (h), isoleucine (i), lysine (k), leucine (l), methionine (m), asparagine (n), proline (p), glutamine (q), arginine (r), serine (s), threonine (t), valine (v), tryptophan (w), or tyrosine (y); (c) growing the plant to produce developed seeds from the plant comprising defenses induced by the defense activators.. .

02/05/15
20150037866 

Composition, method and kit for obtaining purified recombinant proteins


Compositions relating to a combination of two types of separation matrix; and to variant host cells which contain at least one essential host protein that is fused to an affinity binding tag or has been mutated to replace at least two of a plurality of histidines or basic amino acids are provided. Methods are also provided that relate to isolating a recombinant protein from a lysate..
New England Biolabs, Inc.


01/29/15
20150030693 

Anti-tumor aqueous solution, anti-cancer agent, and methods for producing said aqueous solution and said anti-cancer agent


An object of the present invention is to provide an antitumor aqueous solution and an anticancer agent, both of which can kill cancer cells while having virtually no effects on normal cells, and to provide methods for producing the antitumor aqueous solution and the anticancer agent. The method of the invention for producing an antitumor aqueous solution for killing cancer cells includes an aqueous solution preparation step of preparing an aqueous solution through addition, to water, of a solute containing at least one of disodium hydrogen phosphate (na2hpo4), sodium hydrogen carbonate (nahco3), l-glutamine, l-histidine, and l-tyrosine disodium dihydrate (l-tyrosine.2na.2h2o); and a plasma irradiation step of irradiating the aqueous solution with atmospheric pressure plasma generated in a plasma generation region by means of a plasma generator..
Nu Eco Engineeering Co., Ltd.


01/08/15
20150010647 

Methods for identifying fragile histidine triad (fhit) interaction and uses thereof


Provided herein are methods and compositions for the diagnosis, prognosis and treatment of a cancer associated disorders using the fhit gene.. .
The Ohio State University


01/01/15
20150004173 

Compositions and methods for analyzing histidine phosphorylation


A peptide is disclosed of the general structure: z—w—y, wherein z and y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and w is a non-hydrolyzable phis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies.
Sanofi


12/25/14
20140377851 

Analysis device


A reagent including a combination of a polyanionic compound and a bivalent cationic compound contains one substance selected from the group consisting of succinic acid, gluconic acid, alanine, glycine, valine, histidine, maltitol, and mannitol or at least one compound of the substance. A dry state of the reagent and deliquescence can be improved..
Panasonic Healthcare Co., Ltd.


12/25/14
20140377150 

Scandium extraction method


Provided is a method for selectively extracting and inexpensively recovering scandium from an acidic solution containing calcium, magnesium, and scandium. The scandium extraction method according to the present invention involves subjecting an acidic solution containing calcium, magnesium, and scandium to solvent extraction using an extraction agent consisting of an amide derivative represented by the general formula below.
Sumitomo Metal Mining Co.,ltd.


12/18/14
20140370000 

Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph


The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral ph. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral ph.
Baxter Healthcare Sa


12/18/14
20140369992 

C-terminally tethered amino acids and their fibrinolytic therapeutic uses


The present disclosure provides a c-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the c-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins..
Canadian Blood Services


11/27/14
20140349327 

Method for producing fructosyl valyl histidine oxidase preparation


A method for producing a fvho preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, d-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried fvho preparation, comprising a step of allowing bicine to coexist.. .

11/20/14
20140343499 

Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same


A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.

11/20/14
20140343013 

Stabalized glycosaminoglycan preparations and related methods


Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).

11/20/14
20140342994 

Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof


Provided is a fusion protein comprising circularly permuted form of trail, and the fusion protein contains circularly permuted form of trail and oligopeptides located at the n-terminus and/or c-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines.

11/13/14
20140335036 

Hair care conditioning composition comprising histidine


A hair care composition having from about from about 0.025% to about 0.25% by weight of the composition of histidine. The hair care composition further includes a gel matrix phase.

11/06/14
20140330198 

Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same


A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.

11/06/14
20140329711 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.

11/06/14
20140328737 

Cobalt extraction method


The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (i).

10/09/14
20140303099 

Compositions and methods for improving cardiovascular health


Compositions and methods for improving cardiovascular health, especially in the elderly, by delivering a selection of essential amino acids selected from the group of histidine, isoleucine, leucine, valine, lysine, methionine, phenylalanine, threonine, and arginine, which may be supplemented with a low glycemic carbohydrate and/or a medium chain fatty acid.. .

09/25/14
20140287472 

Method for producing l-amino acids using bacteriua of the enterobacteriaceae family


There is disclosed a method for producing l-amino acid, for example l-threonine, l-lysine, l-histidine, l-phenylalanine, l-arginine or l-glutamic acid, using a bacterium of the enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of d-xylose permease.. .

09/25/14
20140286969 

Anti-egfr antibody drug conjugate formulations


The invention provides a stable formulation comprising an anti-egfr antibody drug conjugate (adc), including an anti-egfr antibody, e.g., antibody 1, conjugated to an auristatin, e.g., mmaf, histidine, a sugar, and a surfactant.. .

09/18/14
20140275493 

Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics


Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.

09/18/14
20140274790 

Igg-binding peptide and detecting and purifying igg using same


Provided is a peptide that specifically or selectively binds to human igg. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human igg, wherein the amino acid sequence is represented by formula i: (x1-3)-c-(x2)-h-r-g-(xaa1)-l-v-w-c-(x1-3), wherein, x each independently represents any amino acid residue except cysteine, c represents a cysteine residue, h represents a histidine residue, r represents an arginine residue, g represents a glycine residue, xaa1 represents a glutamic acid residue or an asparagine residue, l represents a leucine residue, v represents a valine residue, and w represents a tryptophan residue..

08/21/14
20140235503 

Prediction glomerular filtration rate from urine samples after kidney transplantation


Disclosed is a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation to provide an information needed for predict renal function after the transplantation, more particularly to a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation, which comprises detecting metabolic profiles of five biomarkers, 5a-androst-3-en-17-one (as), glycocholic acid (gc), sphingosine (sg), tryptophan (tr) and histidine (ht), from urine samples of patients. Glomerular filtration rate (gfr) after kidney transplantation can be predicted more rapidly and precisely to provide an information needed for predict renal function after the transplantation by using five metabolites as biomarkers.

08/21/14
20140234187 

Valuable metal extraction agent and valuable metal extraction method using said extraction agent


The objective of the present invention is to selectively extract light rare earth metals, and by extension, europium, from an acidic solution containing a plurality of types of rare earth metal. This valuable metal extraction agent is represented by the general formula.

08/14/14
20140227728 

Novel fructosyl peptidyl oxidase


In one form, a fructosyl peptidyl oxidase derived from a budding yeast phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying hba1c with higher sensitivity and specificity.

08/07/14
20140220644 

Improved nitrile hydratase


Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.

08/07/14
20140220147 

Pharmaceutical composition comprising factor vii encapsulated in micelles


The invention relates to a pharmaceutical composition comprising factor vii encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the group consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.. .

07/24/14
20140206533 

Organic syringomycin methods and compositions


Methods and materials for producing organic syringomycin, the methods include culturing a culture of pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a ph of from about 6.5 to 7; extracting syringomycin from the culture to yield an extract; and purifying the extract to yield syringomycin.. .

07/24/14
20140205711 

Dipeptides as feed additives


The invention relates to feed additives containing dipeptides or salts thereof, in which one amino acid residue of the dipeptide is a dl-methionyl residue and the other amino acid residue of the dipeptide is an amino acid in the l-configuration selected from lysine, threonine, tryptophan, histidine, valine, leucine, isoleucine, phenylalanine, arginine, cysteine and cystine; feed mixtures containing these additives and method of producing the dipeptides.. .

07/17/14
20140199303 

Stable liquid formulation of etanercept


The present invention relates to a stable liquid formulation of etanercept (recombinant p75 stnfr:fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage.

07/10/14
20140194359 

Interfering rna delivery system and uses thereof


The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.

07/03/14
20140186415 

Polymer composition and polymer material


A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group..

06/26/14
20140179898 

Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent


A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.

06/26/14
20140178460 

Lyase enzymes, nucleic acids encoding them and methods for making and using them


This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.

06/12/14
20140161723 

In vivo methods of monitoring biodistribution


Functional-lipid constructs of the structure f-s-l are disclosed, wherein f comprises a tyrosine or histidine residue, s is a spacer covalently linking f to l and l is a lipid. The functional residue may be iodinated and used to radiolabel a biological entity with 1251 and the iodinated constructs are used in a non-invasive method of monitoring the distribution of a biological entity in vivo..

06/05/14
20140155449 

New use of l-histidine and derivatives thereof


The present invention discloses the use of l-histidine to reduce gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of l-histidine to prevent the nsf syndrome in patients with renal functionality impairment.

06/05/14
20140154752 

Glycoside hydrolases having multiple hydrolase activities


Glycoside hydrolases having at least two different hydrolytic activities are provided. In one embodiment, an isolated recombinant hydrolase having at least two activities selected from a group including asparagine derivatives, glutamine derivatives, and histidine derivatives is provided.

05/29/14
20140148532 

Adhesive composition


A adhesive composition that includes at least the main components of a hydrolyzable tannin and at least one cationic polymer selected from the group including (poly-)lysine, (poly-)-dl-ornithine, ε-poly-ornithine, (poly-)arginine, (poly-)glutamine, (poly-)asparagine, (poly-)histidine, (poly-)proline, putrescine, spermidine, spermine, cadaverine, agmatine, citrulline and mixtures thereof.. .

05/15/14
20140134232 

Encapsulation of plasmid dna (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes


A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between dna with cationic lipid molecules and fusogenic/nls peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or nls at their one end.

05/08/14
20140127693 

Fertilization prediction and promotion


The outcome of an in vitro fertilization (ivf) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (hrg) gene or protein analysis of hrg. The proline isoform of hrg or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman..

05/08/14
20140127144 

Flavour modifying compounds


Wherein r1 is h, or a substituted, unsubstituted, branched or unbranched c1-c5 alkyl group and, nhr2 is a residue of an amino acid, is selected from alanine (ala), cysteine (cys), aspartic acid (asp), phenylalanine (phe), glutamic acid (glu), histidine (his), isoleucine (ile), lysine (lys), leucine (leu), methionine (met), asparagines (asn), glutamine (gln), arginine (arg), serine (ser), theronine (thr), valine (val), tryptophan (trp), tyrosine(tyr) and glycine (gly), with the proviso that the compound is not n-acetyl glycine. Also disclosed are flavour compositions and consumable products containing such compounds..

04/17/14
20140106431 

High fidelity thermostable ligase and uses thereof


The present invention is directed to a mutant thermostable ligase having substantially higher fidelity than either t4 ligase or thermus thermophilus ligase. The ligase of the present invention is a mutant of a wild-type thermostable ligase having a histidine adjacent a kxdg motif, where the mutant thermostable ligase has a mutation in its amino sequence where the histidine adjacent the kxdg motif in the wild-type thermostable ligase is replaced with an arginine, and wherein x is any amino acid.

04/10/14
20140099667 

Bacteriorhodopsin fusion membrane protein expression system


An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a t7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to asn94 of seq id no: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant haloarcula marismortui bacteriorhodopsin/d94n (hmbri/d94n) or a haloquadratum walsbyi bacteriorhodopsin (hwbr); b) a target membrane protein; and c) a t7 promoter, operably linked to the mutant hmbri/d94n or hwbr and the target membrane protein.

04/03/14
20140093472 

L-histidine in ophthalmic solutions


The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight l-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye..

03/27/14
20140088166 

Process of making and using pharmaceutical formulations of antineoplastic agents


In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, l-histidine, l-threonine, l-asparagine, l-serine, l-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.. .

03/20/14
20140082760 

Non-human animals expressing ph-sensitive immunoglobulin sequences


Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.

03/13/14
20140072622 

Vaccine against streptococcus pneumoniae


The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the polyhistidine triad family (e.g.

02/27/14
20140058069 

Particles and other substrates useful in protein purification and other applications


The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments.

02/27/14
20140057328 

Yeast cell for the production of terpenes and uses thereof


The present invention relates to a yeast cell, wherein said cell comprises a functional gene coding for soluble hydroxymethylglutaryl-coenzyme-a (hmg-coa) reductase; one or more gene(s) coding for steryl acyltransferase(s) in said cell are defective or deleted; and said cell is prototrophic for at least histidine, leucine or uracil. Moreover, the present invention relates to the use of said cell for the production of one or more terpene(s).

02/20/14
20140051628 

Composition for long-acting peptide analogs


The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: a-(cm)x-peptide (seq id no: 76), wherein a is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (zyhisw)p (seq id no: 50), wherein z is any amino acid residue other than histidine, his is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if a has alkyl group with 6 to 36 carbon units x is greater than 0; and cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or n-arginine or n-lysine, wherein x is an integer between 0-6 and n may be any amino acid or none.

02/13/14
20140046040 

Method for selective derivatization of oligohistidine sequence of recombinant proteins


Methods and compositions for the selective derivatization of a oligohistidine-tagged recombinant protein. A modifying compound comprised of an imidazole reactive group, a linker, and a ligating group is contacted with the recombinant protein, and a cooperative bond forms between the ligating group and the oligohistidine tag in the presence of a metal cation, and a covalent bond forms between the imidazole reactive group and an imidazole ring of the oligohistidine tag followed by the concomitant separation of the imidazole reactive group from the linker.

02/13/14
20140045244 

Reverse transcriptase having improved thermostability


The present invention relates to a reverse transcriptase having improved thermostability, more precisely a mutant reverse transcriptase with improved thermostability by substitution of one or more amino acids selected from the group consisting of the 63rd glutamine (q63), the 264th lysine (k264), the 295th lysine (k295), the 306th threonine (t306), the 346th glutamic acid (e346), the 408th proline (p408), the 438th histidine (h438), and the 454th asparagin (n454) of the amino acid sequence of m-mlv originated reverse transcriptase represented by seq. Id.

02/13/14
20140044778 

Nanoparticles containing ph-responsive peptide


The present invention provides a nanoparticle and cell induction agent, capable of releasing a target substance in a weakly acidic ph environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with his (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different..

02/13/14
20140044730 

Anti-pcsk9 antibodies with ph-dependent binding characteristics


The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (pcsk9) with greater affinity at neutral ph than at acidic ph. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit ph-dependent binding properties.

02/06/14
20140039158 

Polymeric conjugates and methods of preparing the same


Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the n-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a lysine or a histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the n-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the n-terminal of the target..

02/06/14
20140038856 

Site-specific labeling of affinity tags in fusion proteins


The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula a(b)n, wherein a is a fluorophore, b is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody.

02/06/14
20140037574 

Pharmaceutical composition


The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of cyp3a4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by cyp3a4.

01/30/14
20140031522 

Novel alkali-resistant variants of protein a and their use in affinity chromatography


The present invention relates to immunoglobulin (ig)-binding proteins with alkali-resistance properties. In one embodiment, the present invention provides for a variant of an ig-binding protein, the variant comprising the ig-binding protein having at least one asparagine residue substituted with a histidine, a serine, an aspartic acid or a threonine residue.

01/09/14
20140013456 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.

12/26/13
20130345284 

Sirna compositions and methods for treatment of hpv and other infections


The invention provides sirna compositions that (1) interfere with viral replication of human papillomavirus (hpv), herpes simplex virus (hsv), and human immunodeficiency virus (hiv) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include sirna molecules that target hpv, complexed with a dendrimer that treats and prevents genital herpes (hsv) and hiv.

12/19/13
20130338339 

Affinity chromatography matrix


The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.

11/14/13
20130303377 

Use of single amino acids at low concentrations for influencing the life processes of crops


This invention relates to the use of a composition in low doses containing single l-amino acids, including their precursors and biologically still active metabolites, to influence the life processes of plants, such as their growth, whereby the total amount of single l-amino acids when applying the composition is at least 0.5 g/ha and at most 250 g/ha, and wherein the l-amino acids are selected from the group of glutamine, asparagine, aspartic acid, histidine, lysine, and combinations thereof with each other and/or with arginine and/or with glutamic acid.. .

10/17/13
20130273126 

Tooth bleaching catalytic and application thereof


A method for forming a tooth bleaching catalytic is provided, wherein the method comprises steps as follows: firstly a plurality of histidine-functionalized mesoporous silica nano-particles (msns) is provided. Subsequently, the histidine-functionalized msns are condensating with a plurality of metal ions..

10/10/13
20130267007 

Amadoriase having altered substrate specificity


This invention provides an amadoriase having high substrate specificity to fructosyl valyl histidine. Such amadoriase comprises substitution of one or more amino acid residues at positions corresponding to amino acids selected from the group consisting of position 98, position 259, position 154, position 125, position 261, position 263, position 106, position 103, position 355, position 96, position 66, position 67, position 70, position 100, position 110, position 113, position 114, and position 156 in the amadoriase derived from the genus coniochaeta.

10/03/13
20130261336 

Methods and compositions for increasing the anaerobic working capacity in tissues


Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine..

10/03/13
20130260398 

Phosphohistidine analogs


The present invention relates to the phosphohistidine analogs of the present invention which of the formula (i) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine..

09/19/13
20130247236 

Non-human animals expressing ph-sensitive immunoglobulin sequences


Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.

09/19/13
20130247235 

Mice that produce antigen-binding proteins with ph-dependent binding characteristics


Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.

09/19/13
20130247234 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.

09/05/13
20130230562 

Fusion protein comprising small heat shock protein, cage protein formed thereby, and novel use thereof


The present invention relates to a fusion protein comprising small heat shock protein, a cage protein formed thereby, and novel use thereof, more particularly, a fusion protein comprising a small heat shock protein, a recognition site of a protease, and a histidine polymer, wherein the recognition site and the histidine polymer are sequentially linked to a carboxyl terminal of the small heat shock protein, a cage protein formed thereby, and novel use thereof. The fusion protein of the present invention, and a cage protein formed by the self-assembly properties of the fusion protein are not cytotoxic, and emits a fluorescence signal of about 20 to about 50 times higher comparing to a single peptide for the conventional molecular imaging, per unit protein.

08/22/13
20130216532 

Subcutaneous anti-her2 antibody formulations and uses thereof


The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-her2 antibody, such as e.g. Trastuzumab (herceptin™), pertuzumab or t-dm1, or a mixture of such antibody molecules for subcutaneous injection.



Popular terms: [SEARCH]

Histidine topics: Amino Acid, Amino Acids, Genetically, Antibodies, Immunoglobulin, Polypeptide, Nucleic Acid, Pertuzumab, Trastuzumab, Mesoporous Silica, Hemoglobin, Specificity, Carrier Molecule, Blood Plasma, Recombinant

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.


5.2562

4546

459570 - 0 - 101